ViiV Readies Entry To HIV PrEP Market After Apretude Approval
Executive Summary
A long-acting injectable formulation of cabotegravir, Apretude could result in greater patient adherence to therapy, ViiV claims. The product will be priced at $3,700 per vial.
You may also be interested in...
Three Firms Sign Up With MPP For Long-Acting Cabotegravir
Three generics firms – Aurobindo, Cipla and Viatris’s Mylan – have signed licensing agreements with the Medicines Patent Pool that will allow them to produce versions of ViiV Healthcare’s long-acting cabotegravir treatment for HIV pre-exposure prophylaxis.
Three Firms Sign Up With MPP For Long-Acting Cabotegravir
Three generics firms – Aurobindo, Cipla and Viatris’s Mylan – have signed licensing agreements with the Medicines Patent Pool that will allow them to produce versions of ViiV Healthcare’s long-acting cabotegravir treatment for HIV pre-exposure prophylaxis.
Merck & Co Resumes Islatravir HIV Studies After Safety Concerns, But Abandons PrEP Approach
After a nine-month US FDA-imposed pause, Merck is relaunching its studies of islatravir with a lower dose, while also abandoning its use in PrEP studies.